BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 15257418)

  • 21. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET.
    Dose Schwarz J; Bader M; Jenicke L; Hemminger G; Jänicke F; Avril N
    J Nucl Med; 2005 Jul; 46(7):1144-50. PubMed ID: 16000283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology.
    Amthauer H; Denecke T; Rau B; Hildebrandt B; Hünerbein M; Ruf J; Schneider U; Gutberlet M; Schlag PM; Felix R; Wust P
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31(6):811-9. PubMed ID: 14762698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy.
    Berriolo-Riedinger A; Touzery C; Riedinger JM; Toubeau M; Coudert B; Arnould L; Boichot C; Cochet A; Fumoleau P; Brunotte F
    Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1915-24. PubMed ID: 17579854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correcting tumour SUV for enhanced bone marrow uptake: retrospective 18F-FDG PET/CT studies.
    Teo BK; Badiee S; Hadi M; Lam T; Johnson L; Seo Y; Bacharach SL; Hasegawa BH; Franc BL
    Nucl Med Commun; 2008 Apr; 29(4):359-66. PubMed ID: 18317301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans.
    Freedman NM; Sundaram SK; Kurdziel K; Carrasquillo JA; Whatley M; Carson JM; Sellers D; Libutti SK; Yang JC; Bacharach SL
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):46-53. PubMed ID: 12483409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postinjection transmission scanning in myocardial 18F-FDG PET studies using both filtered backprojection and iterative reconstruction.
    van der Weerdt AP; Boellaard R; Knaapen P; Visser CA; Lammertsma AA; Visser FC
    J Nucl Med; 2004 Feb; 45(2):169-75. PubMed ID: 14960632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of chemotherapy response in osteosarcoma with FDG-PET.
    Hamada K; Tomita Y; Inoue A; Fujimoto T; Hashimoto N; Myoui A; Yoshikawa H; Hatazawa J
    Ann Nucl Med; 2009 Jan; 23(1):89-95. PubMed ID: 19205843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lesion-based detection of early chemosensitivity using serial static FDG PET/CT in metastatic colorectal cancer.
    Buvat I; Necib H; Garcia C; Wagner A; Vanderlinden B; Emonts P; Hendlisz A; Flamen P
    Eur J Nucl Med Mol Imaging; 2012 Oct; 39(10):1628-34. PubMed ID: 22710958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters.
    Westerterp M; Pruim J; Oyen W; Hoekstra O; Paans A; Visser E; van Lanschot J; Sloof G; Boellaard R
    Eur J Nucl Med Mol Imaging; 2007 Mar; 34(3):392-404. PubMed ID: 17033848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
    Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
    Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of (18)F-FDG PET.
    Etchebehere EC; Macapinlac HA; Gonen M; Humm K; Yeung HW; Akhurst T; Scher HI; Larson SM
    Q J Nucl Med; 2002 Jun; 46(2):122-30. PubMed ID: 12114875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
    Groheux D; Hindié E; Giacchetti S; Hamy AS; Berger F; Merlet P; de Roquancourt A; de Cremoux P; Marty M; Hatt M; Espié M
    Eur J Cancer; 2014 Jul; 50(11):1864-71. PubMed ID: 24841218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG PET.
    Nishiyama Y; Yamamoto Y; Kanenishi K; Ohno M; Hata T; Kushida Y; Haba R; Ohkawa M
    Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):287-95. PubMed ID: 17943281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of reconstruction iterations on 18F-FDG PET/CT standardized uptake values.
    Jaskowiak CJ; Bianco JA; Perlman SB; Fine JP
    J Nucl Med; 2005 Mar; 46(3):424-8. PubMed ID: 15750154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI.
    Cheon GJ; Kim MS; Lee JA; Lee SY; Cho WH; Song WS; Koh JS; Yoo JY; Oh DH; Shin DS; Jeon DG
    J Nucl Med; 2009 Sep; 50(9):1435-40. PubMed ID: 19690035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.
    Williams JM; Rani SD; Li X; Arlinghaus LR; Lee TC; MacDonald LR; Partridge SC; Kang H; Whisenant JG; Abramson RG; Linden HM; Kinahan PE; Yankeelov TE
    Med Phys; 2015 Jul; 42(7):3801-13. PubMed ID: 26133582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.
    Hellwig D; Gröschel A; Graeter TP; Hellwig AP; Nestle U; Schäfers HJ; Sybrecht GW; Kirsch CM
    Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):13-21. PubMed ID: 16151765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of dual-time combined 18-fluorodeoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery.
    Capirci C; Rubello D; Pasini F; Galeotti F; Bianchini E; Del Favero G; Panzavolta R; Crepaldi G; Rampin L; Facci E; Gava M; Banti E; Marano G
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1461-9. PubMed ID: 19419820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT.
    Bienert M; McCook B; Carr BI; Geller DA; Sheetz M; Tutor C; Amesur N; Avril N
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):778-87. PubMed ID: 15772860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generation of parametric K
    Wu J; Liu H; Ye Q; Gallezot JD; Naganawa M; Miao T; Lu Y; Chen MK; Esserman DA; Kyriakides TC; Carson RE; Liu C
    Med Phys; 2021 Sep; 48(9):5219-5231. PubMed ID: 34287939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.